During 2024, the United States dominated the Fabry disease therapeutics landscape, capturing nearly 52% of the overall 7MM market and generating close to USD 880 million in revenue, making it the top regional contributor. The market is projected to grow significantly through 2034. Fabry disease is a rare inherited X-linked disorder caused by mutations in the alpha-galactosidase gene, leading to progressive multi-organ damage. Although expanded newborn screening initiatives are facilitating earlier detection, a considerable number of adult patients still experience severe complications by midlife.
Current treatment approaches mainly consist of enzyme replacement therapies (ERTs) and pharmacological chaperone therapies. Prominent therapies such as FABRAZYME, REPLAGAL, GALAFOLD, and ELFABRIO adopt varied mechanisms to address enzyme deficiency. FABRAZYME continues to be the most widely utilized ERT in the United States, whereas REPLAGAL maintains strong usage across Europe and Japan. ELFABRIO, the most recently approved therapy, has received approval in both the US and EU, with additional regulatory steps underway to support monthly dosing regimens.
The competitive landscape includes key players such as Amicus Therapeutics, Sanofi (Genzyme), Takeda, CHIESI–Protalix, Sangamo Therapeutics, and uniQure. The pipeline comprises several promising therapies including Venglustat, ST-920 gene therapy, and other candidates like lucerastat, 4D-310, and AMT-191, although certain programs have faced safety and efficacy challenges. Early-stage assets, including AceLink’s AL01211, are also showing encouraging preliminary results.
Ongoing advancements in clinical trials, progress in gene therapy technologies, increasing awareness about the disease, and enhanced diagnostic capabilities are expected to drive sustained market growth and improve patient outcomes in Fabry disease.
DelveInsight’s “Fabry Disease Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth evaluation of the disease, covering historical and forecasted epidemiology along with market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The study assesses current treatment approaches, emerging therapies, individual drug performance, and market forecasts from 2020 to 2034 across the seven major markets. It further analyzes treatment pathways, major growth drivers, existing limitations, and unmet needs to identify future opportunities and evaluate the overall market potential.
Request for a Free Sample Report @ Fabry Disease Market Forecast
Key Highlights from the Fabry Disease Market Report
- DelveInsight anticipates that the Fabry disease market will expand at a consistent CAGR through 2034.
- According to estimates, the Fabry disease market across the 7MM reached approximately USD 1.7 billion in 2024.
- In 2022, diagnosed prevalent Fabry disease cases in the 7MM were estimated at 15,290, with numbers expected to increase during the 2019–2034 period.
- Key companies operating in this space include Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, uniQure, Codexis, MP6 Therapeutics, CellGenTech, and others.
- Upcoming therapies expected to enter the market include PRX-102 (Pegunigalsidase alfa), Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, and other pipeline candidates.
Recent Developments
- February 2026: Sangamo Therapeutics reported detailed findings from the Phase 1/2 STAAR trial evaluating ST-920 (isaralgagene civaparvovec), its gene therapy candidate for Fabry disease.
- January 2026: Idorsia published results from the Phase 3 MODIFY study and its extension trial for lucerastat, highlighting its potential to address unmet needs, especially in patients with kidney impairment.
- January 2026: Chiesi and Protalix announced that the EMA’s CHMP recommended approval of a reduced dosing frequency (every four weeks) for pegunigalsidase alfa in stable adult patients.
- November 2025: The FDA accepted Sangamo’s rolling BLA submission for ST-920 gene therapy.
- May 2025: All patients in Sangamo’s ST-920 study completed one-year follow-up, enabling progress toward accelerated approval.
- March 2025: Sangamo confirmed alignment with the FDA for an accelerated approval pathway for ST-920.
- February 2025: Amicus Therapeutics presented updates on migalastat programs at the WORLD Symposium.
- January 2025: Idorsia projected Phase III extension data availability in Q2 2025, followed by regulatory discussions.
- January 2025: Sanofi announced plans for regulatory submissions of venglustat in 2026.
- December 2024: CHIESI and Protalix reported EMA validation for a reduced dosing schedule for pegunigalsidase alfa.
- September 2024: uniQure highlighted progress in its Phase I/IIa gene therapy program with expected early results in 2025.
- March 2024: Sanofi released Phase 4 data on improved infusion protocols for Fabrazyme.
- April 2024: 4D Molecular Therapeutics shared Phase 1/2a trial results for 4D-310 in Fabry patients with cardiac involvement.
Fabry Disease Overview
Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the GLA gene, resulting in deficient α-galactosidase A enzyme activity. This leads to the accumulation of globotriaosylceramide (Gb3) across multiple organs, including the kidneys, heart, and nervous system. Clinical symptoms range from neuropathic pain and gastrointestinal issues to severe complications such as kidney failure, cardiomyopathy, arrhythmias, and stroke. Although both genders can be affected, disease severity varies, with late-onset cases being more common and often diagnosed in adulthood. Advances in genetic testing and newborn screening are improving early detection rates. Current treatments include ERTs such as FABRAZYME and REPLAGAL, along with chaperone therapy like GALAFOLD. Emerging therapies, including substrate reduction and gene therapies, aim to deliver more durable and targeted treatment outcomes.
Learn more about Fabry Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Fabry Disease Drugs Market
Fabry Disease Market Outlook
The Fabry disease therapeutics market across the 7MM reached approximately USD 1.7 billion in 2024, with the United States contributing around 52% (~USD 880 million). Europe followed, with Germany leading (~USD 210 million), while Spain contributed the smallest share (~USD 82 million). Japan accounted for nearly USD 150 million, representing about 9% of the total market.
ERTs such as FABRAZYME, REPLAGAL, and ELFABRIO, along with the oral therapy GALAFOLD, continue to form the foundation of treatment. GALAFOLD is effective in roughly 35–50% of patients with suitable GLA mutations. However, ERTs face challenges such as frequent intravenous administration and the development of anti-drug antibodies.
Pipeline therapies including venglustat, ST-920, 4D-310, and AMT-191 aim to improve enzyme delivery and introduce gene-based treatment approaches. Market growth is being driven by rising prevalence, improved diagnostics, and strong pipeline innovation, although challenges such as unmet pediatric needs and long-term efficacy concerns remain.
Fabry Disease Market Drivers
- Growing awareness and early diagnosis through expanded newborn screening
- Limited approved therapies driving demand for innovation
- Strong pipeline of next-generation ERTs, SRTs, and gene therapies
- Regulatory approvals and expanded indications for therapies like ELFABRIO and GALAFOLD
- Significant unmet medical needs due to progressive disease burden
Fabry Disease Market Barriers
- High treatment costs, especially for ERTs and advanced therapies
- Complex disease presentation due to phenotypic variability
- Lack of curative options; gene therapies still under development
- Clinical setbacks and safety concerns in certain pipeline programs
- Small patient population limiting commercial scalability
Fabry Disease Epidemiology
In 2024, the United States reported approximately 9,200 diagnosed prevalent Fabry disease cases, accounting for nearly 52% of the 7MM total. The EU4 and UK contributed about 38%, while Japan represented around 10%. Germany recorded the highest number of cases in Europe (~2,170), while Spain reported the lowest.
Within the US, late-onset Fabry disease represented the majority (~5,860 cases), compared to approximately 3,300 classic phenotype cases. By age distribution, prevalence peaked in the 10–19 age group (~1,920 cases), followed by 20–29 (~1,780), 30–39 (~1,700), 40–49 (~1,430), and around 1,180 cases in individuals aged 50 and above.
These trends highlight the predominance of late-onset disease and emphasize the need for early diagnosis and timely intervention.
Learn more about Fabry Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Fabry Disease Drugs Market
Fabry Disease Epidemiology Segmentation
- Overall diagnosed prevalent cases of Fabry disease
- Gender-wise distribution of diagnosed cases
- Age-based segmentation of diagnosed population
- Classification based on disease phenotype
Fabry Disease Competitive Landscape
Venglustat (Sanofi/Genzyme):
An oral substrate reduction therapy designed to inhibit glucosylceramide synthase, thereby lowering glycosphingolipid accumulation. Phase III trial results are anticipated in the second half of 2025, with possible regulatory filings expected in 2026.
Lucerastat (Idorsia):
A small-molecule substrate reduction therapy applicable across multiple genotypes. Although it did not meet its primary endpoint in the Phase III MODIFY trial, extended study data expected in Q2 2025 may provide further insights.
ST-920 / Isaralgagene civaparvovec (Sangamo):
A liver-targeted AAV-based gene therapy delivering a functional GLA gene via a single intravenous administration. Discussions around accelerated approval are ongoing, with a Biologics License Application (BLA) submission planned for the latter half of 2025.
AMT-191 (uniQure):
An AAV5-mediated gene therapy aimed at providing a one-time correction of enzyme deficiency. The therapy is currently in Phase I/IIa development and has received orphan drug and fast-track designations.
Request for a sample report to understand more about the Fabry Disease pipeline development activities @ Fabry Disease Clinical Trials and FDA Approvals
Fabry Disease Pipeline Therapies and Key Companies
- PRX-102 (Pegunigalsidase alfa): Protalix Biotherapeutics
- Venglustat: Sanofi Genzyme
- ST-920: Sangamo Therapeutics
- FLT190: Freeline Therapeutics
- 4D-310: 4D Molecular Therapeutics
- Lucerastat: Idorsia Pharmaceuticals
- Moss-aGal: GREENOVATION BIOTECH GMBH
Fabry Disease Therapeutics Assessment
Key pharmaceutical and biotech companies are actively engaged in advancing innovative treatment options within the Fabry disease therapeutics space. These efforts are expected to significantly shape the future treatment landscape. Major contributors include Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, uniQure, Codexis, MP6 Therapeutics, CellGenTech, Protalix, and others.
Learn more about the emerging Fabry Disease therapies & key companies @ Fabry Disease Treatment Market
Fabry Disease Report Key Insights
- Patient population analysis for Fabry disease
- Market size evaluation and trend analysis
- Competitive landscape and cross-market competition
- Market dynamics including drivers and barriers
- Identification of growth opportunities
- Overview of therapeutic approaches
- Pipeline and drug development analysis
- Current treatment practices and algorithms
- Impact assessment of emerging therapies
Table of Contents
- Key Findings and Insights
- Executive Overview
- Competitive Intelligence Analysis
- Market Snapshot of Fabry Disease
- Disease Background and Clinical Overview
- Patient Journey Analysis
- Epidemiology and Patient Population Insights
- Treatment Algorithms and Current Medical Practices
- Unmet Needs in Fabry Disease
- Key Clinical Endpoints
- Approved and Marketed Therapies
- Emerging Treatment Options
- Analysis Across the Seven Major Markets
- Attribute-Based Analysis
- Market Outlook Across 7MM
- Access and Reimbursement Landscape
- Key Opinion Leader (KOL) Perspectives
- Market Growth Drivers
- Market Challenges and Barriers
- Appendix Section
- Overview of DelveInsight Capabilities
- Disclaimer
About DelveInsight
DelveInsight is a prominent life sciences market research and consulting firm known for delivering high-quality syndicated reports as well as customized business solutions tailored to organizations operating within the healthcare industry.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting